A comprehensive pipeline review of the Huntington’s disease (HD) therapeutic pipeline is essential for identifying promising new treatments. This monogenic neurodegenerative disorder, characterized by deterioration of motor, cognitive, and behavioral symptoms, is one of the top unmet needs for patients with HD. As the disease’s pathogenesis remains largely unknown, new approaches are needed to address these unmet needs. The following pipeline review outlines the key pharmaceutical companies with HD programs.
